Quantcast

Latest CTLA-4 Stories

2014-06-03 12:36:41

ImaginAb Expands Portfolio for Immunotherapeutic Drug Development LOS ANGELES, June 3, 2014 /PRNewswire/ -- ImaginAb, Inc. and the Regents of the University of California, Los Angeles (UCLA) have executed a technology licensing agreement relating to novel immune cell-targeting agents for imaging with Positron Emission Tomography (PET). Inflammation and immune response play a fundamental role in a wide variety of diseases including cancer and autoimmune diseases. Under the agreement,...

2014-06-01 08:20:34

NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being developed as a potential treatment for multiple cancers. The results were presented today at the 2014 ASCO...

2013-05-27 10:43:58

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ignore cancer cells. Regulatory T cells are immune cells that function to suppress the immune system response. In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors...

2011-09-16 11:28:21

Some of the newest therapies in the war on cancer remove the brakes cancer puts on the immune system, Georgia Health Sciences University researchers report. These immunotherapies, such as CTLA4, strengthen the immune system's attack on cancer by keeping apart two proteins that prevent key immune cells called T cells from activating. Research featured on the cover of the Journal of Immunology suggests that these therapies also keep tumors from benefitting from IDO, an enzyme used by...

117736034
2011-08-22 13:01:29

The first new skin cancer treatment since the 1970s has now gone on sale in Britain, according to a Monday morning article by Telegraph Health Correspondent Martin Beckford. The drug is known as ipilimumab, and according to the American Cancer Society, it is "a type of immunotherapy known as a monoclonal antibody," which is definite as "a man-made version of an immune system protein that fits like a lock and key with a certain protein in the body." "Ipilimumab is designed to seek out...

2011-04-05 08:00:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer. Preclinical data demonstrated anti-tumor efficacy in a murine model as a monotherapy, and further enhanced...

2011-03-25 19:04:34

First drug approved in more than a decade The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been shown to offer a survival benefit for metastatic melanoma, which is often a fatal disease, and hopefully, this will lead to the development of related treatments for...

2010-05-03 10:42:27

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine. The two-year results from the three-year BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) and BENEFIT-EXT ("extended criteria") studies were presented Sunday at the...

2009-07-08 14:00:25

Transplant patients rely on drugs to prevent graft rejection, but at the cost of serious side effects. The class of immunosuppressive drugs known as calcineurin inhibitors (examples are cyclosporine and tacrolimus) can damage patients' kidneys and lead to high blood pressure, among other problems.A combination of treatments can effectively replace calcineurin inhibitors in preventing graft rejection when kidney transplants are performed on monkeys, scientists at the Emory Transplant Center...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related